Leerink Partnrs Has Negative Outlook of MRSN FY2025 Earnings

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Equities researchers at Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for Mersana Therapeutics in a research report issued on Monday, March 3rd. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings per share of ($0.63) for the year, down from their prior forecast of ($0.43). The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for Mersana Therapeutics’ FY2026 earnings at ($0.18) EPS.

A number of other equities research analysts have also issued reports on MRSN. William Blair initiated coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They issued an “outperform” rating on the stock. Wedbush restated an “outperform” rating and issued a $4.00 price objective on shares of Mersana Therapeutics in a research report on Monday. Finally, Citigroup started coverage on Mersana Therapeutics in a research report on Friday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.25.

Mersana Therapeutics Stock Up 2.5 %

MRSN stock opened at $0.53 on Wednesday. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. The company’s 50 day simple moving average is $0.77 and its 200-day simple moving average is $1.55. Mersana Therapeutics has a 12 month low of $0.46 and a 12 month high of $6.28. The firm has a market capitalization of $64.88 million, a PE ratio of -0.86 and a beta of 1.39.

Mersana Therapeutics (NASDAQ:MRSN) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $16.36 million for the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%.

Institutional Investors Weigh In On Mersana Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Mackenzie Financial Corp purchased a new stake in Mersana Therapeutics in the 4th quarter valued at about $131,000. Sphera Funds Management LTD. purchased a new stake in Mersana Therapeutics in the fourth quarter valued at approximately $987,000. Nuveen Asset Management LLC grew its holdings in Mersana Therapeutics by 53.6% in the fourth quarter. Nuveen Asset Management LLC now owns 232,223 shares of the company’s stock valued at $332,000 after purchasing an additional 81,022 shares during the period. Millennium Management LLC increased its position in Mersana Therapeutics by 206.4% during the fourth quarter. Millennium Management LLC now owns 795,973 shares of the company’s stock worth $1,138,000 after purchasing an additional 536,190 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in Mersana Therapeutics by 12.0% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,111,998 shares of the company’s stock worth $1,590,000 after purchasing an additional 118,952 shares during the period. Hedge funds and other institutional investors own 93.92% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.